Autoimmune Polyendocrinopathy.

Clicks: 194
ID: 32036
2019
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Star

Ranked #30 of 44 articles by views in the journal of clinical endocrinology and metabolism

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
This mini-review offers an update on the rare autoimmune polyendocrinopathy syndrome (AP) with a synopsis of recent developments.Systematic search for studies related to pathogenesis, immunogenetics, screening, diagnosis, clinical spectrum, and epidemiology of AP.AP (orphan code ORPHA 282196) is defined as the autoimmune-induced failure of at least two glands. AP is divided into the rare juvenile type I and the adult types II to IV. The prevalence is 1:100.000 and 1:20.000 for types I and II-IV, respectively. While type I (ORPHA 3453) is a monogenetic syndrome with an autosomal recessive transmission related to mutations in the AIRE gene, types II-IV are genetically complex multifactorial syndromes that are strongly associated with certain alleles of the human leucocyte antigen (HLA) genes within the major histocompatibility complex located on chromosome 6, as well as the cytotoxic T-lymphocyte antigen 4 and the protein tyrosine phosphatase non-receptor type 22 gene. Addison's disease is the major endocrine component of type II (ORPHA 3143), while the coexistence of type 1 diabetes and autoimmune thyroid disease is characteristic for type III (ORPHA 227982). Genetic screening for the AIRE gene is useful in patients with suspected type I while serological screening (i.e. diabetes/adrenal antibodies) is required in patients with monoglandular autoimmunity and suspected AP. If positive, functional endocrine testing of the antibody positive patients as well as serological screening of their first-degree relatives is recommended.Timely diagnosis, genetic counseling, and optimal long-term management of AP is best offered in specialized centers.
Reference Key
frommer2019autoimmunethe Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Frommer, Lara;Kahaly, George J;
Journal the journal of clinical endocrinology and metabolism
Year 2019
DOI
jc.2019-00602
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.